Reviewing Brainsway (NASDAQ:BWAY) & Jushi (OTCMKTS:JUSHF)

Jushi (OTCMKTS:JUSHF) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

21.7% of Jushi shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 22.5% of Jushi shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Jushi and Brainsway”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jushi	$257.52 million	0.34	-$48.78 million	($0.33)	-1.34
Brainsway	$52.22 million	9.68	$7.63 million	$0.25	51.48

Brainsway has lower revenue, but higher earnings than Jushi. Jushi is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Jushi has a beta of -0.91, meaning that its stock price is 191% less volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Jushi and Brainsway’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jushi	-25.15%	N/A	-15.07%
Brainsway	14.62%	11.10%	6.97%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Jushi and Brainsway, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jushi	0	0	0	1	4.00
Brainsway	0	1	2	1	3.00

Brainsway has a consensus price target of $15.00, suggesting a potential upside of 16.55%. Given Brainsway’s higher possible upside, analysts clearly believe Brainsway is more favorable than Jushi.

Summary

Brainsway beats Jushi on 11 of the 14 factors compared between the two stocks.

About Jushi

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.